Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-140-0 | CAS number: 3010-96-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 50 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Additional information
The potential for 2,2,4,4-tetramethyl-1,3-cyclobutanediol to cause target organ toxicity following repeated exposure is well understood and is based on the results of two studies that followed OECD guidelines 407 and 408, and were conducted under GLP assurances GLP. The first one was a 28-day exposure study whose primary purpose was to determine dose levels to conduct the second key study which consisted of three treatment groups (20 rats/sex/dose) administered test article BID at dose levels of 25, 80, and 240/200 mg/kg (50, 160 and 480/400 mg/kg/day) for 90 days. Controls received distilled water vehicle. The 240 mg/kg/dose BID dose level was lowered to 200 mg/kg BID on Day 43 due to increased mortality. In this study, no test article-related adverse effects were seen on body weight, hematology, coagulation, clinical chemistries, urinalysis, or in macroscopic evaluations at necropsy. There were 11 male and 13 female early deaths in 240/200 mg/kg group and 1 female given 80 mg/kg BID. Cause of death was undetermined in all females and most males. One male from the 240/200 dose group appeared to have died from aspiration of foreign material and another from urogenital/inflammation/obstruction/calculi. Test article-related clinical observations were noted in the 80 and 240/200 mg/kg dose groups. At 80 mg/kg BID clonic convulsions were seen in 1 male in Week 11, 2 males in Week 13, and 1 female in Week 10. Females were hypersensitive to touch and stereotypic behavior was seen in both genders at 80 mg/kg BID. At 240/200 mg/kg BID in addition to clonic convulsions (noted in Weeks 2, 3, 6, and 7), hypersensitive to touch was seen in both genders as well as stereotypic behavior. The stereotypy was most frequently characterized as jumping and rigidity; the rigidity could have also been another convulsion. The highest incidences of convulsions and stereotypy were seen in the first few weeks. The subsequent lower incidence was attributed to lowering the dose level on Day 43. At the end of the 13 -week study, there were no test article-related effects seen in the functional observational battery of tests or motor activity. In the weekly neurobehavioral observations 1 to 2 hours post-dose, the convulsions described above were seen in a few 240/200 mg/kg BID animals. In addition, at 240/200 mg/kg BID the grid activity count data for the males showed increased activity. However, at the end of the 13-week study there was no test article-related effect on motor activity. The possible differences that were noted were sporadic with no relationship to dose. There was a transient test article-related decrease in food consumption for the first week in both the males and females at 240/200 mg/kg BID. All groups consumed a similar amount of food each week after that. Statistically significantly increased mean kidney weights were present in males at 25, 80, and 240/200 mg/kg/dose BID when compared to controls. Mean absolute kidney weights were increased 7%, 12%, and 18% in males at 25, 80, and 240/200 mg/kg/dose BID, respectively. There was no microscopic correlate for the increased weights in kidneys examined and the percent of weight increase was considered not to be biologically significant. Test article-related organ weight changes were also present in adrenal glands. Statistically significantly increased adrenal gland weights were present in males and females at 240/200 mg/kg BID and in males at 80 mg/kg BID (absolute and relative to brain weight) when compared to controls. Mean absolute adrenal gland weights were increased 19% and 41% in males at 80 and 240/200 mg/kg BID, respectively and 33% in females at 240/200 mg/kg BID. The increased adrenal gland weights correlatedmicroscopically to diffuse cortical hypertrophy/hyperplasia. Diffuse cortical hypertrophy/hyperplasia was present in 5 and 8 males at 80 and 240/200 mg/kg BID, respectively and in 2 females at 240/200 mg/kg/dose BID. Diffuse cortical hypertrophy/hyperplasia was characterized by a minimal to mild increase in the size and number of cells in the zonas fasciculata and reticularis of the adrenal cortex. This was the only microscopic finding in the study despite the neurobehavioral changes. Test article-related sperm effect was limited to the significant reduction in total sperm concentration per cauda epididymis and sperm concentration per gram cauda epididymis at 240/200 mg/kg/dose. This was likely a stress related response.In conclusion, under the conditions of this study, where rats were dosed orally for 13-weeks at 25, 80, 240/200 mg/kg/dose BID, the NOAEL was 25 mg/kg BID (50 mg/kg/day).
Repeated dose toxicity: via oral route - systemic effects (target organ) neurologic: behaviour
Justification for classification or non-classification
Based on the toxicological profile of TMCD and weight of evidence no classification for specific Target Organ Toxicity – Repeated Exposure according to GHS is warranted despite the NOAEL being <100 mg/kg. The major effect of behaviour changes was very transient in nature and their was no morphological changes or alterations in the functional operational battery.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
